

# Department of Medicine Division of Renal Medicine

CONTINUING MEDICAL EDUCATION

## SEMINARS in NEPHROLOGY

At the conclusion of this activity participants will be able to:

- Cite key evidence supporting SGLT2 inhibition in improving renal outcomes
- Describe mechanisms of SGLT2 inhibitors in renal protection
- Develop familiarity for managing diabetic nephropathy with SGLT2 inhibitors

## **“Nephrologist-initiated SGLT2 Inhibition in Diabetic Nephropathy?”**

Presented by:  
**Julie Ingelfinger, MD**

Professor of Pediatrics, Harvard Medical School  
Senior Consultant, Massachusetts General Hospital for Children  
Deputy Editor, New England Journal of Medicine

**Tuesday, January 7, 2020**

1:00 p.m. – 2:30 p.m., AS7~2072

UMass Memorial, University Campus

\*All staff are invited and encouraged to attend\*

**Accreditation Statement:** The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement:** The University of Massachusetts Medical School designates this live activity for a maximum of one AMA PRA Category 1 credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Statement on Faculty Disclosure:** It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.